Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: silva d. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Establishing pathological cut-offs for lateral ventricular volume expansion rates.
Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R. Dwyer MG, et al. Among authors: silva d. Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018. Neuroimage Clin. 2018. PMID: 29527505 Free PMC article.
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J. Manouchehrinia A, et al. Among authors: silva dg. Mult Scler. 2019 Jul;25(8):1102-1112. doi: 10.1177/1352458518783667. Epub 2018 Jun 18. Mult Scler. 2019. PMID: 29911467
White matter lesion location correlates with disability in relapsing multiple sclerosis.
Gaetano L, Magnusson B, Kindalova P, Tomic D, Silva D, Altermatt A, Magon S, Müller-Lenke N, Radue EW, Leppert D, Kappos L, Wuerfel J, Häring DA, Sprenger T. Gaetano L, et al. Among authors: silva d. Mult Scler J Exp Transl Clin. 2020 Feb 18;6(1):2055217320906844. doi: 10.1177/2055217320906844. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32128236 Free PMC article.
Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.
Fernández O, Izquierdo G, Aguera E, Ramo C, Hernandez M, Silva D, Walker R, Butzkueven H, Wang C, Barnett M; EARLIMS investigators. Fernández O, et al. Among authors: silva d. Mult Scler J Exp Transl Clin. 2020 Sep 13;6(3):2055217320957358. doi: 10.1177/2055217320957358. eCollection 2020 Jul-Sep. Mult Scler J Exp Transl Clin. 2020. PMID: 32974041 Free PMC article.
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA. DeLuca J, et al. Among authors: silva d. Mult Scler Relat Disord. 2021 Feb;48:102673. doi: 10.1016/j.msard.2020.102673. Epub 2020 Dec 10. Mult Scler Relat Disord. 2021. PMID: 33454584 Free article. Clinical Trial.
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.
Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H. Healy BC, et al. Among authors: silva d. Mult Scler J Exp Transl Clin. 2021 Apr 11;7(2):2055217321999070. doi: 10.1177/2055217321999070. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33953937 Free PMC article.
5,968 results